l-glutamine Improves Skeletal Muscle Cell Differentiation and Prevents Myotube Atrophy After Cytokine (TNF-α) Stress Via Reduced p38 MAPK Signal Transduction

Journal of Cellular Physiology

Volumn 231, Issue 12, 2016, Pages 2720-2732

  Girven, Matthew ^a   Dugdale, Hannah F ^a   Owens, Daniel J ^a,b   Hughes, David C ^a,c   Stewart, Claire E ^a   Sharples, Adam P ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE AMMONIA LIGASE; GLUTAMINE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOGENIN; PROTEIN BID; PROTEIN C FOS; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR;

ADRA1D GENE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL LOSS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; MOUSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE HYPERTROPHY; MYHC2 GENE; MYHC7 GENE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETAL MYOBLAST; TNFSFR1B GENE; UPREGULATION;

EID: 84983247513     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25380     Document Type: Article

References (83)

1. Al-Shanti N, Saini A, Faulkner SH, Stewart CE. 2008. Beneficial synergistic interactions of TNF-α and IL-6 in C2 skeletal myoblasts-potential cross-talk with IGF system. Growth Factors (Chur, Switzerland) 26:61–73.
2. Al-Shanti N, Stewart CE. 2008. PD98059 enhances C2 myoblast differentiation through p38 MAPK activation: A novel role for PD98059. J Endocrinol 198:243–252.
3. Alvarez B, Quinn LS, Busquets S, Lopez-Soriano FJ, Argiles JM. 2001. Direct effects of tumor necrosis factor alpha (TNF-α) on murine skeletal muscle cell lines. Bimodal effects on protein metabolism. Eur Cytokine Netw 12:399–410.
4. Beharry AW, Sandesara PB, Roberts BM, Ferreira LF, Senf SM, Judge AR. 2014. HDAC1 activates FoxO and is both sufficient and required for skelmuscle atrophy. J Cell Sci 127:1441–1453.
5. Bemelmans MH, Greve JW, Gouma DJ, Buurman WA. 1996a. Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality. Gut 38:447–453.
6. Bemelmans MH, van Tits LJ, Buurman WA. 1996b. Tumor necrosis factor: Function, release and clearance. Crit Rev Immunol 16:1–11.
7. Berg A, Forsberg E, Wernerman J. 2002. The local vascular tolerance to an intravenous infusion of a concentrated glutamine solution in ICU patients. Clin Nutr 21:135–139.
8. Berkes CA, Tapscott SJ. 2005. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 16:585–595.
9. Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, Webster SG, Miller SC, Webster C. 1985. Plasticity of the differentiated state. Science 230:758–766.
10. Bode B, Fischer C, Abcouwer S, Wasa M, Souba W. 1996. Glutamine and cancer cachexia. Protein and amino acid metabolism in cancer cachexia. Berlin, Heidelberg: Springer, pp 139–170.
11. Bonetto A, Penna F, Minero VG, Reffo P, Costamagna D, Bonelli G, Baccino FM, Costelli P. 2011. Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-alpha. Amino Acids 40:585–594.
12. Boza JJ, Turini M, Moennoz D, Montigon F, Vuichoud J, Gueissaz N, Gremaud G, Pouteau E, Piguet-Welsch C, Finot PA, Ballevre O. 2001. Effect of glutamine supplementation of the diet on tissue protein synthesis rate of glucocorticoid-treated rats. Nutrition 17:35–40.
13. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011–2015.
14. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JB, Pedersen BK, Jeune B. 2003a. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med 115:278–283.
15. Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK. 2003b. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 132:24–31.
16. Bruunsgaard H, Pedersen BK. 2003. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 23:15–39.
17. Calder PC, Yaqoob P. 1999. Glutamine and the immune system. Amino Acids 17:227–241.
18. Chen SE, Jin B, Li YP. 2007. TNF-α regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 292:C1660–C1671.
19. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR. 1997. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272:6653–6662.
20. Curthoys NP, Watford M. 1995. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 15:133–159.
21. Edstrom E, Altun M, Hagglund M, Ulfhake B. 2006. Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle. J Gerontol A Biol Sci Med Sci 61:663–674.
22. Foulstone EJ, Huser C, Crown AL, Holly JM, Stewart CE. 2004. Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: Roles of IGF-I and TNFalpha. Exp Cell Res 294:223–235.
23. Foulstone EJ, Meadows KA, Holly JM, Stewart CE. 2001. Insulin-like growth factors (IGF-I and IGF-II) inhibit C2 skeletal myoblast differentiation and enhance TNF alpha-induced apoptosis. J Cell Physiol 189:207–215.
24. Foulstone EJ, Savage PB, Crown AL, Holly JM, Stewart CE. 2003. Role of insulin-like growth factor binding protein-3 (IGFBP-3) in the differentiation of primary human adult skeletal myoblasts. J Cell Physiol 195:70–79.
25. Gillespie MA, Le Grand F, Scime A, Kuang S, von Maltzahn J, Seale V, Cuenda A, Ranish JA, Rudnicki MA. 2009. P38-{gamma}-dependent gene silencing restricts entry into the myogenic differentiation program. J Cell Biol 187:991–1005.
26. Greer EL, Brunet A. 2005. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410–7425.
27. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. 2001. Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. FASEB J 15:475–482.
28. Grohmann M, Foulstone E, Welsh G, Holly J, Shield J, Crowne E, Stewart C. 2005a. Iso lation and validation of human prepubertal skelmuscle cells: Maturation and metabolic effects of IGF-I, IGFBP-3 and TNFalpha. J Physiol 568:229–242.
29. Grohmann M, Sabin M, Holly J, Shield J, Crowne E, Stewart C. 2005b. Characterization of differentiated subcutaneous and visceral adipose tissue from children the influences of TNF-α and IGF-I. J Lipid Res 46:93–103.
30. Jejurikar SS, Henkelman EA, Cederna PS, Marcelo CL, Urbanchek MG, Kuzon WM, Jr. 2006. Aging increases the susceptibility of skeletal muscle derived satellite cells to apoptosis. Exp Gerontol 41:828–836.
31. Karinch AM, Pan M, Lin CM, Strange R, Souba WW. 2001. Glutamine metabolism in sepsis and infection. J Nutr 131:2535S–2538S; discussion 2550S–2531S.
32. Keren A, Tamir Y, Bengal E. 2006. The p38 MAPK signaling pathway: A major regulator of skeletal muscle development. Mol Cell Endocrinol 252:224–230.
33. Kim J, Won KJ, Lee HM, Hwang BY, Bae YM, Choi WS, Song H, Lim KW, Lee CK, Kim B. 2009. P38 MAPK participates in muscle-specific RING finger 1-Mediated atrophy in cast-immobilized rat gastrocnemius muscle. Korean J Physiol Pharmacol 13:491–496.
34. Ko HM, Oh SH, Bang HS, Kang NI, Cho BH, Im SY, Lee HK. 2009. Glutamine protects mice from lethal endotoxic shock via a rapid induction of MAPK phosphatase-1. J Immunol 182:7957–7962.
35. Labow BI, Souba WW. 2000. Glutamine. World J Surg 24:1503–1513.
36. Lacey JM, Wilmore DW. 1990. Is glutamine a conditionally essential amino acid? Nutr Rev 48:297–309.
37. Lagranha CJ, Hirabara SM, Curi R, Pithon-Curi TC. 2007. Glutamine supplementation prevents exercise-induced neutrophil apoptosis and reduces p38 MAPK and JNK phosphorylation and p53 and caspase 3 expression. Cell Biochem Funct 25:563–569.
38. Lassar AB. 2009. The p38 MAPK family, a pushmi-pullyu of skeletal muscle differentiation. J Cell Biol 187:941–943.
39. Leger B, Derave W, De Bock K, Hespel P, Russell AP. 2008. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 11:163–175B.
40. Li Y, Jiang B, Ensign WY, Vogt PK, Han J. 2000. Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cell Signal 12:751–757.
41. Li YP. 2003. TNF-α is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 285:C370–C376.
42. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB. 2005. TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. Faseb J 19:362–370.
43. Li YP, Lecker SH, Chen Y, Waddell ID, Goldberg AL, Reid MB. 2003. TNF-α increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. Faseb J 17:1048–1057.
44. Li YP, Reid MB. 2000. NF-kappaB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 279:R1165–R1170.
45. Lluis F, Ballestar E, Suelves M, Esteller M, Munoz-Canoves P. 2005. E47 phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle-specific gene transcription. Embo J 24:974–984.
46. Mackey AL, Kjaer M, Dandanell S, Mikkelsen KH, Holm L, Dossing S, Kadi F, Koskinen SO, Jensen CH, Schroder HD, Langberg H. 2007. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl Physiol (1985) 103:425–431.
47. Manjavachi MN, Motta EM, Marotta DM, Leite DF, Calixto JB. 2010. Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Pain 151:345–355.
48. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. 2002. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg 183:471–479.
49. Meadows KA, Holly JM, Stewart CE. 2000. Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 183:330–337.
50. Mikkelsen UR, Langberg H, Helmark IC, Skovgaard D, Andersen LL, Kjaer M, Mackey AL. 2009. Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise. J Appl Physiol (1985) 107:1600–1611.
51. Molkentin JD, Black BL, Martin JF, Olson EN. 1995. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 83:1125–1136.
52. Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, Marquez VE, Valente S, Mai A, Forcales SV, Sartorelli V, Puri PL. 2010. TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7:455–469.
53. Parry-Billings M, Evans J, Calder PC, Newsholme EA. 1990. Does glutamine contribute to immunosuppression after major burns? Lancet 336:523–525.
54. Philip B, Lu Z, Gao Y. 2005. Regulation of GDF-8 signaling by the p38 MAPK. Cell Signal 17:365–375.
55. Reid MB, Li YP. 2001. Cytokines and oxidative signalling in skeletal muscle. Acta Physiol Scand 171:225–232.
56. Roth E, Funovics J, Muhlbacher F, Schemper M, Mauritz W, Sporn P, Fritsch A. 1982. Metabolic disorders in severe abdominal sepsis: Glutamine deficiency in skeletal muscle. Clin Nutr 1:25–41.
57. Saini A, Al-Shanti N, Faulkner SH, Stewart CE. 2008. Pro- and anti-apoptotic roles for IGF-I in TNF-α-induced apoptosis: A MAP kinase mediated mechanism. Growth Factors (Chur, Switzerland) 26:239–253.
58. Saini A, Al-Shanti N, Sharples AP, Stewart CE. 2012. Sirtuin 1 regulates skeletal myoblast survival and enhances differentiation in the presence of resveratrol. Exp Physiol 97:400–418.
59. Saini A, Al-Shanti N, Stewart C. 2010. C2 skeletal myoblast survival, death, proliferation and differentiation: Regulation by Adra1d. Cell Physiol Biochem 25:253–262.
60. Saini A, Al-Shanti N, Stewart CE. 2006. Waste management − cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17:475–486.
61. Salehian B, Mahabadi V, Bilas J, Taylor WE, Ma K. 2006. The effect of glutamine on prevention of glucocorticoid-induced skeletal muscle atrophy is associated with myostatin suppression. Metabolism 55:1239–1247.
62. Sandri M. 2008. Signaling in muscle atrophy and hypertrophy. Physiology 23:160–170.
63. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399–412.
64. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 3:1101–1108.
65. Schubert R, Geiger H, Zielen S, Baer PC. 2009. Simultaneous detection of ERK-, p38-, and JNK-MAPK phosphorylation in human adipose-derived stem cells using the Cytometric Bead Array technology. J Immunol Methods 350:200–204.
66. Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. 2008. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab 7:33–44.
67. Sharples AP, Al-Shanti N, Hughes DC, Lewis MP, Stewart CE. 2013. The role of insulin-like-growth factor binding protein 2 (IGFBP2) and phosphatase and tensin homologue (PTEN) in the regulation of myoblast differentiation and hypertrophy. Growth Horm IGF Res 23:53–61.
68. Sharples AP, Al-Shanti N, Stewart CE. 2010. C2 and C2C12 murine skeletal myoblast models of atrophic and hypertrophic potential: Relevance to disease and ageing? J Cell Physiol 225:240–250.
69. Sharples AP, Hughes DC, Deane CS, Saini A, Selman C, Stewart CE. 2015a. Longevity and skeletal muscle mass: The role of IGF signalling, the sirtuins, dietary restriction and protein intake. Aging Cell 14:511–523.
70. Sharples AP, Polydorou I, Hughes DC, Owens DJ, Hughes TM, Stewart CE. 2015b. Skeletal muscle cells possess a 'memory' of acute early life TNF-α exposure: Role of epigenetic adaptation. Biogerontology [Epub ahead of print]: DOI: 10.1007/s10522-015-9604-x.
71. Singleton KD, Beckey VE, Wischmeyer PE. 2005. Glutamine prevents activation of NF-kappaB and stress kinase pathways, attenuates inflammatory cytokine release, and prevents acute respiratory distress syndrome (ARDS) following sepsis. Shock (Augusta, Ga) 24:583–589.
72. Stewart CE, Newcomb PV, Holly JM. 2004. Multifaceted roles of TNF-α in myoblast destruction: A multitude of signal transduction pathways. J Cell Physiol 198:237–247.
73. Stewart CE, Newcomb PV, Savage PB, Dickens M, Tavare J, Holly JM. 1999. Increased, not decreased activation of the insulin-like growth factor (IGF) receptor signalling pathway during ceramide-induced apoptosis. Growth Horm IGF Res 9:131–142.
74. Tollefsen SE, Sadow JL, Rotwein P. 1989. Coordinate expression of insulin-like growth factor II and its receptor during muscle differentiation. Proc Natl Acad Sci USA 86:1543–1547.
75. Tolosa L, Morla M, Iglesias A, Busquets X, Llado J, Olmos G. 2005. IFN-gamma prevents TNF-α-induced apoptosis in C2C12 myotubes through down-regulation of TNF-R2 and increased NF-kappaB activity. Cell Signal 17:1333–1342.
76. van de Vyver M, Myburgh KH. 2012. Cytokine and satellite cell responses to muscle damage: Interpretation and possible confounding factors in human studies. J Muscle Res Cell Motil 33:177–185.
77. Wang F, Nguyen M, Qin F, Tong Q. 2007. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 6:505–514.
78. Watford M. 2015. Glutamine and glutamate: Nonessential or essential amino acids? Anim Nutr 1:119–122.
79. Wernerman J. 2008. Clinical use of glutamine supplementation. J Nutr 138:2040s–2044s.
80. Wischmeyer PE, Riehm J, Singleton KD, Ren H, Musch MW, Kahana M, Chang EB. 2003. Glutamine attenuates tumor necrosis factor-alpha release and enhances heat shock protein 72 in human peripheral blood mononuclear cells. Nutrition 19:1–6.
81. Yaffe D, Saxel O. 1977. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270:725–727.
82. Yang S, Alnaqeeb M, Simpson H, Goldspink G. 1996. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil 17:487–495.
83. Zhan M, Jin B, Chen S-E, Reecy JM, Li Y-P. 2007. TACE release of TNF-α mediates mechanotransduction-induced activation of p38 MAPK and myogenesis. J Cell Sci 120:692–701.